project year

2025

Advanced pre-clinical evaluation of sphingosine kinase 1-targeting agents as a therapy for acute myeloid leukaemia

Advancing CAR-T cell therapy for extracranial solid paediatric cancers

Creating the Next Generation in Radiotherapy Imaging with Carbon Nanotube Sources and Photon Counting Detectors

Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Engineering childhood cancer for precision medicine

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Improving our understanding of the oncogenic signalling-metabolism nexus to design better treatments for pancreatic cancer

Leveraging stem-like memory T cells for effective anti-cancer mRNA vaccines

MARCH5 is a master regulator of BCL2 proteins and a potential anti-cancer drug target

Pan-cancer assessment of sensitivity towards novel selective oncogenic JNK inhibitors

Predicting clinical response to breast cancer therapy – the immune signature approach

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Selective manipulation of tumour-stroma signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

Help us to put an end to cancer